Bullflag on 4h - Target 75On 4h chart a nice (and perfect) bullflag is in the making, and ready to breakout, with a target of 75.
QLong
NEL is about to break out (if it crosses 23.5NEL needs to push just a little bit further up to break out. So, wait for now.
If it breaks out then reaching 30 is possible quite soon.
Long
Long
QLong
PHOTOCURE buying opportunitySo I can be quick on Photocure.
We are in a nice long uptrend, which is currently hitting resistance, forming an ascending triangle.
The only sure strategy here is to wait for a break and retest of this triangle.
#Ultimovacs $ULTI announce FOURTH randomized phase 2 trial FOCUSNote that information about the third study is still expected before year end.
Ultimovacs ASA – Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab
Oslo, 22 December 2020: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), today announced the initiation of FOCUS, a Phase II randomized clinical trial that will evaluate the Company’s proprietary universal cancer vaccine, UV1, in 75 patients with recurrent or metastatic head and ne
ULong
AKERBP at major resistance. AKERBP has managed to fill the gap it left behind in March of this year at NOK 222,10.
However, currently we've arrived at historical strong resistance, furthermore, we have the 200MA (weekly) just above as well.
The most likely scenario is a retrace before an attempt to break this resistance.
So where to look?
I see a nice confluence of the top of the weekly cloud and the 0.382 fib on the latest impulse on the weekly chart around NOK 194,50).
Of course a lot can happen, but I will be paying a
Long
Analyst increase Photocure $PHO price target to 130 (125) ABG Sundal Collier: Photocure - Q3: a solid stepping stone towards expansion
Q3 results due 10 November US recovery and EU commercialisation in the spotlight Tweaking near term ests. – DCF TP up to NOK 130 (125)
Long
MPCC Bullish IdeaUptrend is showing us good results, the next strong resistance at 8.00, 47% from Todays price (5.58)
Long
QLong
Short
MOWI - Short Term Long Position ~ 10% ^I believe this is a pretty strong / secure analysis.
Reasons:
- Chart is leading up to a breakout.
- Positive fundamentals lately such as positive financials Q3, positive salmon news and recent large investments.
- Recent breakout of negative trend.
Long
Short
Long
Long
Long
RLong
Soon Ready for breakout From this Triangel.Using 4 h chart. And Here we have had a ABC correction Wawe. So i think the next wawe will be on the moore powerfull to the oppside.
RSI breakout and MACD Crossing. So here i think we gonna breakout soon. The momentum is on the way uppwards.
They produce Silisum and have a Factory in Moss lake. that is ready to support the west whith silisum. Its the mineral we are using in the solarpanels.
So huge demand in the Future.
RLong
Targovax has the cheapest oncolytic virus on the marketONCOS-102 is one of the most promising oncolytic viruses with >200 patients treated.
Targovax stock has been under pressure for years after equity offerings at fairly low pricing, but has been making a strong move recently, quite without many investors taking notice.
Norwegian Biotech especially in the field of cancer immunotherapy may be ready for a new round of interest after the recent news about Vaccibody partnering with Genentech.
Long
#Softox $SOFTX nordic #biofilm medtech with US defence grantSoftOx Solutions AS is a Scandinavian medtech company, founded in 2012, listed at Euronext Growth with new ticker OSL:SOFTX . After years of research and product development with leading Nordic research institutions, SoftOx has developed a non-toxic and highly efficient antiseptic technology, which eradicates and prevents biofilm infections and is fully virucidal.
THESE PRODUCTS ARE CURRENTLY UNDER DEVELOPMENT
Human Wound & Infection Treatments
SoftOx is developing a range of products that c
Long
$NEL Hydrogen crush previous ATH, $NKLA signs MOU with $GMAlso recent Bank of America BUY with price target 30 NOK
Long